Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dalotuzumab + Cetuximab + Irinotecan in Metastatic Colorectal Cancer
NCT00614393Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Dec 2007
- Primary completion
- Jun 2010
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
01
Overview
A Phase 2 trial of dalotuzumab in metastatic colorectal cancer (mCRC), sponsored by Merck & Co.. Started Dec 2007; status: completed.
02
Drugs
dalotuzumab
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT00614393.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00614393.